Meeting
2018 ASCO Annual Meeting
A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.
Authors
Alexandra Leary
Gustave Roussy Cancer Campus, Villejuif, France
Alexandra Leary , Philippe Georges Aftimos , Jean-Pierre Delord , Christophe Le Tourneau , Isabelle Laure Ray-Coquard , Christiane Jungels , Andrea I. Varga , Francesco Ricci , Carlos Alberto Gomez-Roca , Guillaume Bataillon , Nathalie Van Acker , Grégory Noël , Olivier Lantz , Lydie Cassard , Agnès Coste , Bérengère Jean , Isabelle Marie Tabah-Fisch , Anne Vincent- Salomon , Jean-François Prost , Ahmad Awada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02978755
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5542)
DOI
10.1200/JCO.2018.36.15_suppl.5542
Abstract #
5542
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2017 ASCO Annual Meeting
Prognostic implications of TAMs in colorectal cancer hepatic metastases.
First Author: Matthew Reilley
Poster
2016 ASCO Annual Meeting
Tumor-infiltrating CD204+ M2 macrophages compared to T cells as a prognosticator for patients with uterine cervical adenocarcinoma.
First Author: Asuka Kawachi
Poster
2014 ASCO Annual Meeting
Incidence and localization of tumor-infiltrating CD163+ macrophages and T-cells in early breast cancer patients.
First Author: Anna Koumarianou